Pfenex and DNA2.0 have entered an R&D agreement for genes to be expressed by Pfenex Expression Technology. DNA2.0 will develop an optimized algorithm and process for the design and synthesis of genes to be expressed in Pseudomonas fluorescens, the microorganism used in the Pfenex’ platform.
“Pfenex is dedicated to the rapid and reliable production of high-quality recombinant proteins for our partners,” notes Bertrand Liang, M.D., CEO of Pfenex. “Through this collaboration, two industry leaders will leverage their respective capabilities to advance the Pfenex Expression Technology platform. We are very excited about this project with our long-standing gene synthesis partner, DNA2.0, because it allows us to enhance the capabilities of our technology, which will enable us to increase the overall value proposition to our partners.”
Jeremy Minshull, Ph.D., cofounder and CEO of DNA2.0, says, “Our patented GeneGPS™ technology is based on experiment data from over-expressed synthetic genes, resulting in up to a 100-fold increase in protein expression. We have successfully optimized expression for a variety of hosts including bacteria, yeast, fungus, plant, and mammalian, and we are excited to work with Pfenex to extend our expertise to the P. fluorescens system.”
Pfenex is a protein production company and produces research proteins, reagent proteins, biosimilars, and innovator biopharmaceuticals. DNA2.0 offers an integrated pipeline of solutions for the research community, including gene design, optimization, synthesis, and cloning, as well as platforms for protein and strain engineering.